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Vam10p defines a Sec18p-independent step of
priming that allows yeast vacuole tethering
Masashi Kato and William Wickner*
Department of Biochemistry, Dartmouth Medical School, 7200 Vail Building, Hanover, NH 03755-3844
Contributed by William Wickner, April 11, 2003
YOR068c, termed VAM10 (altered vacuole morphology), lies within
the VPS5 gene on the opposite DNA strand. VAM10 deletion causes
vacuole fragmentation in vivo. The in vitro fusion of purified yeast
vacuoles is stimulated by recombinant Vam10p and blocked by
antibody to Vam10p. Vam10p acts early in the priming stage of
fusion, independent of Sec18p. After priming, recombinant
Vam10p will not stimulate fusion and anti-Vam10p antibodies will
not inhibit; Vam10p provides a functional marker for this Sec18p-
independent priming step. Pure Vam10p restores normal, Ypt7p-
dependent tethering to vacuoles from a vam10 strain.
Membrane fusion is regulated and catalyzed by similarfactors for each organelle and organism (1). These include
RabYpt and Rho family GTPases, their nucleotide exchange
and GTPase-activating proteins, other tethering proteins and
effectors, soluble N-ethylmaleimide-sensitive fusion proteins
(SNAREs), SNARE-associated proteins such as the Munc18
Sec1 family, chaperones, phosphoinositides, sterols, actin, cal-
cium, and calcium-binding proteins. The complexity of regulated
trafficking and membrane fusion suggests that additional factors
remain to be discovered.
We study membrane fusion mechanisms with yeast vacuoles
(2). Homotypic vacuole fusion occurs in three stages: (i) priming,
which precedes vacuole association, (ii) tethering and docking, in
which vacuoles form clusters, and (iii) fusion, the mixing of the
bilayers and luminal contents. Sec18p ATPase drives Sec17p
release during priming (3), disassembling the cis–SNARE com-
plex. In addition to Sec18p action, lipid synthesis (4) and
acylation of Vac8p (5) occur during priming. Docking occurs in
three subreactions: tethering, vertex ring assembly, and trans-
SNARE pairing. Tethering is mediated by the Ypt7p GTPase
(6). Ypt7p is enriched at a ‘‘vertex ring’’ microdomain that
surrounds the apposed membranes of tethered vacuoles (7).
Conversion of Ypt7p to its GTP-bound form and remodeling of
vacuolar actin allow the SNAREs, the HOPSVPS class C
effector complex, and actin to assemble into the vertex ring (7,
8). The assembled ring allows trans-SNARE pairing. Fusion is
initiated by a flux of calcium from the vacuole lumen (9).
A genomic approach has identified genes involved in vacuole
fusion (10). We screened a commercially available yeast library
of nonessential gene deletions for their vacuole morphology;
deletion of a vacuole fusion gene causes fragmented vacuoles.
Among the strains with abnormal vacuole morphology (vam
phenotype; ref. 11) were 28 ORFs encoding proteins of unknown
function.
We now report that one ORF, YOR068c (VAM10), catalyzes
an early and novel stage of the priming subreaction, a stage that
can proceed independently of Sec18p and ATP-mediated dis-
assembly of the cis–SNARE complex. Vam10p acts during
priming to permit vacuole tethering.
Methods
Yeast Strains. Strains BJ3505 and DKY6281 have been described
(12). Deletions of yor068c, ydr136w, and vps5 in BY4742 were
purchased from Research Genetics (Huntsville, AL). Deletions
of pep4 or pho8 were made in vam10 (yor068c) as described (9).
Yor068p and Ybr174p were overexpressed in yeast strain Y258,
fused to GST-HisX6 at their NH2 termini, and expressed from
GAL1 (ref. 13; a gift from M. Snyder, Yale University, New
Haven, CT).
Proteins. Proteins tagged with C-terminal maltose binding pro-
tein (MBP) were expressed in Escherichia coli BL21(DE3)
(Novagen) with pMAL-c2x (New England Biolabs) containing
in-frame EcoRI–XbaI (vam10) or EcoRI–BamHI (ydr136c)
PCR products. MBP-tagged full-length Yor068p and truncated
Ydr136p (61 aa; from ‘‘FALPR’’ to ‘‘PPHGE’’) were purified by
amylose affinity chromatography (New England Biolabs).
Whole-cell lysates were prepared as described (14). IgG was
prepared by Sephacryl S-200 HR gel filtration (Pharmacia) after
isolation on protein A Sepharose CL-4B (Pharmacia). Vam10p
antibody was affinity-purified on peptide crosslinked to Affi-Gel
10 (Bio-Rad).
Vacuole Fusion. Standard reactions contained 3 g of each of
frozen vacuoles from BJ3505 and DKY6281 in 30–35 l of
reaction buffer (10 mM Pipes-KOH, pH 6.8200 mM sorbitol
125 mM NH4Cl5 mM MgCl210 M CoA8 g/ml IB21 mM
Mg-ATP40 mM creatine phosphate0.5 mg/ml creatine kinase
6.6 ng/ml leupeptin16.6 ng/ml pepstatin16.6 M o-
phenanthroline3.3 M Pefabloc SC). After 90 min at 27°C,
alkaline phosphatase was assayed (12).
Yeast Expression of Vam10p and Vps5p. The pRS316 vector, this
vector bearing VPS5 and VAM10 (nucleotides 453367–456210)
or bearing this fragment with a T-to-A mutation at residue
454213, abolishing VAM10 expression by changing its initiator
Met codon to a Lys codon while not changing the amino acyl
residues encoded on the opposite strand (for VPS5), was trans-
formed into wild-type, vam10, or vps5 yeast. The latter
deletion is the 3 end of the VPS5 gene, shown in the unshaded
box in Fig. 3A. To do this, the VPS5 gene with its native promoter
and terminator (and with a point mutation in the start codon of
VAM10, where indicated) was amplified by PCR, using
CCCAAGCTTTCGCGGCAGTCTTC and CCGCTCGAG-
GTTACACCAACAAAAGA with HindIII and XhoI sites. The
point mutation was made by the QuikChange site-directed
mutagenesis kit (Stratagene), using CCAAATACT-
TCAAAAAGCTTCTCTGGAAGAAGATCCGG and CCG-
GATCTTCTTCCAGAGAAGCTTTTTGAAGTATTTGG.
The plasmid pRS316 (New England Biolabs) without insert or
bearing the PCR product encoding both VPS5 and VAM10 or
these genes with T454213A was transformed into BY4742,
BY4742 bearing deletion of vam10 (and the corresponding 5
region of the vps5 genes), and BY4742 bearing deletion of
nucleotides 454858–455796, the 3 region of vps5. Transfor-
mants were selected on SD-ura (Bio 101) and screened for
integration by RT-PCR, using ATGGACTACGAGGATA-
ATCT (5-VPS5), CTAAAGATTGGTTTGGTAGAA (3-
VPS5), AAGTATTTGGTGAAGTGTTAG (5-VAN10), and
Abbreviations: SNARE, soluble N-ethylmaleimide-sensitive fusion protein; YPD, yeast
extractpeptonedextrose.
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AATATCTACAAATGAAGAAAGAA (3-VAM10), and by
the presence or absence of a HindIII site (AAGCTT).
Results
Vacuoles are fragmented when YOR068c is deleted (Fig. 1A; ref.
10) or overexpressed from a plasmid under GAL regulation (Fig.
1B). Vacuoles normally fuse on exposure of cells to low osmo-
larity (16); these in vivo fusion events were counted during a
30-sec window 3 min after cells were transferred to hypoosmolar
medium. Deletion of YOR068c prevented osmotic stress-induced
vacuole fusion in vivo (Fig. 1C, lane 2).
In accord with these in vivo studies, the YOR068c-encoded
protein (068p), fused to MBP, stimulates in vitro vacuole fusion.
To assay fusion, we isolate vacuoles from two strains, one with
normal proteases but lacking the PHO8 phosphatase, the other
with a normal PHO8 gene but lacking luminal proteases and,
thus, with catalytically inactive proPho8p. On fusion, proPho8p
is cleaved to the mature active enzyme (12). Stimulated fusion
(Fig. 2A, lane 2 vs. 6) was blocked by antibody to Vam3p (lane
7), showing that it is on the normal fusion pathway. MBP or other
protein fusions with MBP did not stimulate (Fig. 2B). Other pure
proteins, such as Sec18p and calmodulin, caused similar stimu-
lation of fusion (Fig. 2 A, lane 4; also see ref. 17), but combina-
tions of these proteins with YOR068p did not enhance fusion
(data not shown). Antibody to Vam10p (or Fab; data not shown)
inhibited the fusion of purified vacuoles (Fig. 2C, lanes 2–4).
Inhibition was dose dependent and was reversed by the addition
of recombinant Vam10p (Fig. 2D). Further studies also point to
a direct role for YOR068c in vacuole fusion, and, therefore, we
name this protein Vam10p (11).
The VAM10 gene is in a cluster of membrane-trafficking genes
(Fig. 3A). It lies within VPS5, encoded on the opposite DNA
strand. Genetic studies distinguish the functions of VAM10 and
VPS5. Deletion of the VAM10 gene causes a large deletion in the
5 domain of VPS5, which we term vps5-5, whereas deletion
from 454858 to 455796 in the 3 domain of VPS5 (unshaded
VPS5-3 box; Fig. 3A) leaves the VAM10 gene intact. Yeast with
Fig. 1. Vacuole fusion in vivo. (A) Wild-type (WT) strain BY4742 (a) and
yor068c (b) were grown in 0.2 ml of yeast extractpeptonedextrose (YPD) in
15-ml culture tubes at 30°C. After 16 h, 0.4 ml of YPD with 5 M FM4–64 (15)
was added, incubation was continued for 4 h at 30°C, and cells were photo-
graphed (7). (B) Vacuole morphology before and after induction of Vam10p
(a and b) and Ybr174p (c and d) by galactose. (C) Osmotic stress-induced
vacuole fusion. WT strain BY4742 (lane 1) and yor068 (lane 2), vps5-3 (lane
3), and ydr433w strains were grown in 0.5 ml of YPD in 15-ml culture tubes
at 30°C. After 16 h, 1 ml of YPD with 5 M FM4–64 was added and incubation
was continued at 30°C until OD600  5 (4–5 h). Samples (400 l) were centri-
fuged (6,000  g for 30 sec) and cells were resuspended in 350 l of water.
After 3 min at 23°C, in vivo vacuole fusion events were counted for 4 min in
eight fields (30 sec per field). The average and SD of five experiments are
presented. (D) Vector pRS316-transformed WT strain BY4742 (lane 1) and
yor068c (lane 2), vps5 (lane 3), and pVPS5-transformed yor068c (lane 4)
strains were grown in 0.5 ml of SD-ura medium and analyzed as above.
Fig. 2. YOR068p promotes vacuole fusion. (A) Fusion reactions with vacuoles
from BJ3505 and DKY6281 were performed with anti-Vam3p antibody (1M),
calmodulin (CaM; 20 M), his6-Sec18p (0.1 M), or MBP-tagged Vam10p
(Vam10p; 8 M) as indicated. (B) Fusion reactions contained the indicated
concentrations of MBP, Yor068p, or Ydr136p, each with an MBP tag. (C) Fusion
reactions bore control buffer (lanes 1 and 2) or the indicated concentrations
of anti-Vam10p (lanes 3 and 4) or anti-Ydr433p antibody. These IgG antibodies
were purified as described (18). (D) Standard fusion reactions contained PS
buffer (10 mm Pipes-KOH, pH 6.8200 mm sorbitol; lanes 1 and 2) or the
indicated concentrations of anti-Vam10p antibody (IgG fraction; lanes 3 and
5–7) andor Vam10p (lanes 4–7).
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each of these deletions, as well as the isogenic wild type, was
purchased. RT-PCR analysis shows that each deletion ablates
the corresponding transcript (Fig. 3B). Deletion of VAM10 also
abolishes the production of full-length VSP5 transcript (Fig. 3B,
lane 13), whereas deletion of the 3 half of VPS5 allows VAM10
transcription (lane 7). Plasmid p(VAM10 and VPS5) was pre-
pared (Fig. 3C) that expresses both the normal VAM10 and VPS5
genes. A derivative plasmid with a T454213A mutation abolishes
the start codon for VAM10 but leaves the normal amino acid
sequence of Vps5p (Fig. 3C); this plasmid is termed pVPS5.
Control vector, the vector expressing Vam10p and Vps5p, and
the vector expressing Vps5p alone were transformed into wild-
type BY4742 or into this strain deleted for VAM10 (and, hence,
the 5 domain of VPS5) or for the 3 domain of VPS5. Vacuole
morphology was examined in each of these strains (Fig. 3D).
Whereas BY4742 wild-type yeast have one to three vacuoles in
most cells (Fig. 3D, 1), vam10 (vps5-5) or vps5-3 causes
fragmentation (Fig. 3D, 4 and 7). Coexpression of Vps5p and
Vam10p from p(VAM10 and VPS5) cures the vacuole fragmen-
tation in vam10 (vps5-5) or vps5-3 backgrounds (Fig. 3 D5
and D8). However, expression of Vps5p alone cures the vps5-3
phenotype (Fig. 3D9) but does not cure the vam10 (vps5-5)
phenotype (Fig. 3D6), establishing a distinct role for Vam10p in
vacuole morphology. Quantitation of vacuole number in cells
from multiple microscopy fields (Fig. 3E) confirms these visual
impressions. Thus, Vam10p and Vps5p each are needed for
normal vacuole morphology.
With these strains, we returned to the in vivo assay of
osmolarity-induced fusion to distinguish the roles of Vam10p
and Vps5p. Vacuole fusion (Fig. 1D, lane 1) was abolished by the
deletion of VAM10 and, hence, truncation of VPS5 (lane 2).
Intermediate fusion rates were seen when only one of the VPS5
or VAM10 genes was expressed (lanes 3 and 4). Thus, both
VAM10 and VPS5 are required for normal vacuole fusion.
Further studies may determine whether Vps5p has a direct role
in vacuole fusion or only governs vacuole morphology through its
role in biosynthetic protein delivery to the vacuole.
Vam10p is needed on at least one vacuole in a fusion pair (Fig.
4A). Our in vitro fusion assay was performed with vacuoles from
pep4 and pho8 strains that were vam10 (vps5-5), with
expression of Vps5p, or both Vps5p and Vam10p, from plasmids.
The absence of Vam10p from even one of the two vacuoles
inhibited fusion (lanes 4 and 6), but fusion was abolished by the
complete absence of Vam10p (lane 8). This was not due to a
deficiency in Pep4p or Pho8p (Fig. 4B). Many other proteins
known to be required for fusion also were present at normal
levels in the absence of Vam10p (Fig. 4C). Carboxypeptidase Y
was present at normal levels in vacuoles from cells lacking
Vam10p, showing that VAM10 is not a VPS gene. Strikingly,
Sec18p, the HOPS subunits Vps39p and Vps41p, and actin were
enriched on vacuoles lacking Vam10p (Fig. 4C). Each of these
proteins is involved in early stages of the reaction, suggesting that
Vam10p may function early in the fusion pathway.
To determine where Vam10p acts, we analyzed the kinetics
with which vacuoles acquired resistance to antibodies to
Vam10p. Fusion reaction aliquots either were placed on ice,
RNA origins of the RT-PCR products (data not shown). (C) Plasmids for gene
expression were prepared as described in Methods. (D) Vacuole morphology
was examined in WT, vam10 (vps5-5), and vps5-3 strains bearing the
control plasmid (pRS316), p(VAM10 and VPS5), or pVPS5 prepared as in B
above, which were grown in 0.5 ml of SD-ura medium in 15-ml tubes at 30°C.
After 16 h, 1 ml of YPD with 5 M FM4–64 was added, incubation was
continued for 4 h, and vacuole morphology was examined. Pictures of multi-
ple fields were taken for each condition. (E) For each of the strains shown in
D, the percentage that have one to three, four to six, or more than seven
vacuoles was scored for 120–160 cells.
Fig. 3. Relationship of VPS5 and VAM10. (A) Map of the ALG8, VAM10, VPS5,
GYP1 region. The VPS5 gene encompasses 2,028 bp (shaded plus open boxes
in the figure), from 453769 to 455796 (19, 20), although only residues 454858–
455796 were removed in the vps5 strain. The VAM10 gene lies within the
VPS5 gene on the opposite strand. (B) Levels of mRNA from ALG8, VAM10,
VPS5, and GYP1 genes in BY4742 and BY4742 mutants bearing deletions,
which were assayed by RT-PCR by using the oligonucleotides listed in C for
VPS5 and VAM10 and GGCTCCATTGTCGCCG (5-ALG8), TCACTGCCATAGTA-
ATTCGT (3-ALG8), TACACAGGCCTGTTGTTTG (5-GYP1), and TTACAGCCAGT-
GCGACGT (3-GYP1). RNA preparation used RNase-free DNase I and TRIzol
(Invitrogen). Samples also were analyzed without the RT step to confirm the
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mixed with buffer, or mixed with antibody to Vam10p, to Sec17p
or Sec18p (which catalyze priming), or to Vam3p to inhibit
docking (Fig. 5A). All incubations were continued to 90 min,
when samples were assayed for active, mature Pho8p. Each
inhibitor completely blocked fusion when added at the start of
the incubation. The reaction rapidly became resistant to anti-
body to Sec17p or Sec18p, reflecting their early priming role.
Resistance to anti-Vam10p (Fig. 5A) occurred in parallel with
resistance to antibody to Sec17p or Sec18p, suggesting that
Vam10p functions exclusively during priming. Fusion reactions
also were performed with the addition of either recombinant
Vam10p or buffer at various times. Fusion was stimulated when
Vam10p was added at early reaction times but not after 15 min
of incubation (Fig. 5B). Clearly, Vam10p only acts early in the
reaction.
Are Vam10p and Sec1718p activities related? Anti-Sec18p
blockade is reversed by the addition of recombinant Sec18p (3).
Fig. 4. Fusion activity and protein composition of vacuoles from vam10
cells. (A) Standard fusion assays were performed with vacuoles from VAM10,
pep4; VAM10, pho8-; vam10-, pep4-; and vam10-, pho8- strains.
(B and C) Vacuoles (6 g) from each indicated strain were analyzed by
immunoblotting.
Fig. 5. Vam10p acts at a novel priming stage. (A) Reactions (1,350 l) had
BJ3505 and DKY6281 vacuoles and 4 M Vam10p. Aliquots (30 l) were
placed on ice or added to inhibitors [anti-Sec17p (final concentration, 1
M), anti-Sec18p (1 M), anti-Vam3p (1 M), and anti-Vam10p (4.9 M)] at
the indicated times. After 90 min, alkaline phosphatase was measured. (B)
Aliquots (30 l) were removed from a standard fusion reaction (300 l) and
added to PS buffer or to Vam10p (final concentration, 8 M) at the
indicated times. After 90 min, phosphatase was assayed. (C) Standard
fusion reactions contained 8 M Vam10p (lanes 2, 4, and 5) and 0.33 M
anti-Sec18p antibody (lane 5) at 4°C (lanes 1 and 2) or 27°C (lanes 3–5).
Certain reactions were started with 0.33 M anti-Sec18p in the presence
(lanes 8 and 11) or absence (lanes 6, 7, 9, and 10) of 8M Vam10p under plus
(lanes 6 – 8) or minus (lanes 9 –11) ATP conditions. After 20 min at 27°C,
samples received 8 M Vam10p (lanes 7 and 10), ATP (lanes 9 –11), or PS
buffer. After further incubation for 70 min at 27°C, phosphatase was
measured. (D) Fusion reactions contained 4 M Vam10p (lanes 5 and 6), 8
M anti-Vam10p (lanes 4 and 6), or 0.33M anti-Sec18p (lane 3) at 4°C (lane
1) or 27°C (lanes 2– 6). Reactions were started with 0.33 M anti-Sec18p
with 4 M Vam10p (lanes 7 and 8). After 20 min at 27°C, samples received
0.16 M Sec18p with (lane 7) or without (lane 8) 8 M anti-Vam10p. After
70 min at 27°C, phosphatase was measured. (E) After incubating fusion
reactions with vacuoles from wild-type or yor068 strains with 0.018 M
Sec18p for the indicated times, vacuoles were removed by centrifugation
and supernatants were analyzed by immunoblotting with anti-Sec17p (3).
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Vacuole fusion (Fig. 5C, lane 3) was stimulated by Vam10p (lane
4) on the normal fusion pathway as it was inhibited by anti-
Sec18p (lane 5). A two-step incubation was begun with anti-
Sec18p for 20 min followed by recombinant Sec18p. Vam10p
stimulation was seen only when Vam10p was present from the
start of the reaction (lanes 6–8), even when ATP was omitted
from the first incubation (lanes 9–11).
To show that Vam10p can act before Sec18p, a two-step reaction
was used, exploiting Sec18p reversal of anti-Sec18p inhibition (3)
and the capacity of anti-Vam10p to block the stimulation of fusion
by Vam10p (Fig. 5D, lanes 5 and 6). When vacuoles first are
incubated with Vam10p in the presence of anti-Sec18p and then
mixed with sufficient antibody to Vam10p to block stimulation of
fusion and given Sec18p, full fusion activity is seen (lanes 7 and 8).
Accordingly, vacuoles from a vam10 strain show normal release
of Sec17p (Fig. 5E). Vam10p is the first vacuole fusion factor that
can act upstream of Sec18p, although our data do not address
whether it must act upstream of Sec18p.
Vacuole priming is a prerequisite for tethering, the first
association between vacuoles. Tethering (Fig. 6A, 1) is abolished
by Gdi1p (Fig. 6A, 2), which extracts Ypt7p (20). Strikingly,
vam10- vacuoles do not tether (Fig. 6A, 3) unless pure Vam10p
is added (Fig. 6A, 4). Vam10p-mediated tethering of vam10
vacuoles is still fully sensitive to Gdi1p (Fig. 6A, 5). Quantitation
of the intervacuole contacts in multiple image fields (Fig. 6B)
confirms the visual impressions. Thus, Vam10p is an ATP-
independent priming factor, not coupled to Sec18p action or
Sec17p release, which supports subsequent vacuole tethering.
Discussion
Vam10p is needed for vacuole fusion in vivo and in vitro. The
VAM10 gene lies within VPS5, yet it has a distinct function (Fig.
3). VAM10 deletion does not lower vacuolar CPY (Fig. 4C) and
thus is not a VPS gene. The in vivo role of Vam10p was confirmed
by its being required for osmotic stress-induced fusion and by the
vacuole fragmentation induced by Vam10p overexpression. In
vitro, we find that Vam10p stimulates vacuole fusion, and
antibody to Vam10p blocks fusion during priming. Vam10p has
no detectable effect on Sec17p release, suggesting that it affects
another early process. This is likely a new function, as the known
events of priming all require ATP, whereas Vam10p can act
before ATP addition. However, the strongly enhanced vacuolar
levels of peripheral membrane proteins such as Sec18p, HOPS,
and actin in the absence of Vam10p suggests that Vam10p might
function in a release stage of their normal cycling between the
vacuole and cytoplasm. Vam10p has no obvious homologs, in
yeast or in other sequenced organisms, although it is in a cluster
of trafficking genes between ALG8 and GYP1. Because each
aspect of vacuole fusion is conserved functionally in other
membrane-fusion events (2), Vam10p may have functional, if not
sequence, homologs in other fusion reactions.
The stages of priming that are needed for tethering are complex.
Tethering needs neither Vam3p nor Vam7p, and the Ypt7p on
tethered vacuoles is enriched in vertex rings (8). Ligands to ergos-
terol (22) and phosphoinositides (4) can inhibit during priming, and
these lipids might have a role in establishing the vertex ring of Ypt7p
in conjunction with Vam10p. The striking effect of Vam10p on the
levels of vacuolar HOPS, Sec18p, and actin is in accord with their
roles in early steps of the fusion pathway. (i) Vps41p, a subunit of
the HOPS complex, has altered mobility and abundance in the
absence of Vam10p (Fig. 4C); because both Ypt7p and Vam10p are
needed for tethering, and HOPS is a Ypt7p–effector complex (23),
this may reflect the functional role of Vam10p. (ii) Vacuoles from
vam10 strains bear more Sec18p (Fig. 4C), suggesting a connec-
tion between these two priming factors. (iii) Actin disassembly,
which is sensitive to jasplakinolide, is needed for an early docking
stage of the reaction, because jasplakinolide allows Ypt7p-
dependent tethering (14) but fusion becomes jasplakinolide-
resistant sometime between Ypt7p action and the completion of
docking (14). Our working model is that Vam10p participates in
tethering along with Ypt7p, regulating crucial vacuole-bound pro-
teins. Other functions for Vam10p could be to regulate phospho-
inositide synthesis or turnover; to control the essential vacuolar
gradients of protons, calcium, or other ions that are established in
vitro during priming; or to interact with Vtc complex (24), SNARE
complex, Ypt7p, actin, or other vacuolar proteins that act during
priming and tethering.
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Fig. 6. Vam10p supports tethering. (A) Docking assays (7) had 6 g of
vacuoles from BY4742 (1 and 2) or vam10 (3–5), with reaction buffer (10 mM
Pipes-KOH, pH 6.8200 mM sorbitol40 mM KCl0.1 mM MgCl210 M CoA
0.3 mM ATP6 mM creatine phosphate10 units/ml creatine kinase7.5 ng/ml
leupeptin37.5 ng/ml pepstatin3.75 M o-phenanthroline7.5 M Pefabloc
SC). After 25 min at 27°C, samples were chilled and stained with 5M FM4–64
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